No abstract

No abstract

The therapy of Toxoplasma retinochoroiditis with atovaquone is well tolerated. Our data suggests that therapy with atovaquone has the potential to prolong the time to recurrence of Toxoplasma retinochoroiditis. A prospective randomized comparative long-term clinical trial would be necessary to confirm our data.

IOP reduction by a pure mechanical procedure like oculopression leads to a significant increase of flow velocities of the retrobulbar vessels. This effect can significantly be increased by using dorzolamide prior to oculopression.